drm02

DRM02 is a small molecule pyrazolylbenzothiazole derivative developed as a selective phosphodiesterase 4 (PDE4) inhibitor for topical use in inflammatory skin disorders. It acts by inhibiting PDE4 isoforms A, B, and D with high potency (IC50 values in the submicromolar range), leading to reduced production of pro-inflammatory cytokines in keratinocytes and immune cells. Additionally, DRM02 inhibits nuclear factor-kappaB (NF-κB) transcriptional activity and decreases expression of adhesion molecules such as ICAM-1. In preclinical models and early clinical trials, it demonstrated anti-inflammatory effects in conditions like atopic dermatitis and psoriasis. The drug was originally developed by QLT and later advanced by Dermira; development was discontinued after phase 2 trials for atopic dermatitis, plaque psoriasis, and rosacea[1][2][3][4].

Other names

drm02drm-02drm 02VAL-002VAL002VAL 002